Powered by knowledge and fueled by passion, our scientific excellence has resulted in FDA-approved products, including treatments for diseases with no prior approved therapies.
Jakafi® (ruxolitinib) was the first FDA-approved JAK inhibitor for any indication and the first FDA-approved product in all three of its current indications.
Pemazyre® (pemigatinib) was also approved1 by the FDA for an indication that previously had no approved therapies for patients.
Opzelura™ (ruxolitinib) cream, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is the first and only FDA-approved topical JAK inhibitor approved for certain patients with mild to moderate atopic dermatitis (AD).
We acquired the rights to Iclusig® (ponatinib) through an exclusive license from Takeda Pharmaceuticals International in the European Union and 29 other countries, including Switzerland, Norway, Turkey, Israel and Russia. In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally. Monjuvi® (tafasitamab-cxix)2 is being co-commercialized by Incyte and MorphoSys in the U.S., and Incyte has exclusive commercialization rights outside the U.S.
Beyond our in-house development portfolio, Incyte scientists discovered two additional approved medicines: Olumiant® (baricitinib), developed and commercialized by our partner Eli Lilly, and Tabrecta® (capmatinib), developed and commercialized by our partner Novartis.
Because patients are our top priority, a significant portion of our revenue is reinvested into R&D in our effort to Solve On.